U.S. pharma large copyright scrapped two experimental weight loss products last 12 months—a the moment-daily tablet, lotiglipron, resulting from elevated liver enzymes along with a 2 times-everyday pill, danuglipron, resulting from strong Unintended effects—but CEO Albert Bourla has reported the company is determined to “Enjoy and earn” in